Spinal Cord Injury stem cell therapy — your questions answered (2026)

About stem cell therapy for Spinal Cord Injury

Spinal cord injury varies by neurological level, completeness, cause and time since injury. Research includes neural progenitors, oligodendrocyte-lineage products, MSCs, scaffolds and exosomes with different goals and risks. An injection near or into the spinal cord does not establish cell survival, circuit integration, restored walking or recovery of bladder and bowel function.

The evidence for Spinal Cord Injury

Early trials often focus on feasibility and safety. Interpretation requires exact product, injury level and completeness, time window, route, surgery, rehabilitation dose, comparator, blinded neurological and functional outcomes and long-term tumour, infection and worsening-risk surveillance. The FDA consumer alert states that the promoted regenerative products it addresses are not approved in the United States to treat neurological disorders. Natural recovery and intensive rehabilitation must be separated from product effect.

Separate product and surgery from imaging, admission, rehabilitation, equipment, accessible travel, caregiver support, follow-up and management of infection, pain, spasticity or neurological deterioration. Do not divert resources from pressure care, respiratory, bladder, bowel, mobility and psychosocial support.

Can stem cells repair a spinal cord injury?

Cell therapy for Spinal Cord Injury may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

How long after injury can I start?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

Acute vs chronic — which responds?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU programme cost?

The partner-published indicative range for an Spinal Cord Injury programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Spinal Cord Injury (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗

← Back to Spinal Cord Injury overview · Spinal Cord Injury cost →